A New Series of Estrogen Receptor Modulators That Display Selectivity for Estrogen Receptor β
Brad R. Henke, Thomas G. Consler, Ning Fei Go et al. · Journal of Medicinal Chemistry · 2002
A series of 1,3,5-triazine-based estrogen receptor (ER) modulators that are modestly selective for the ERbeta subtype are reported. Compound 1, which displayed modest potency and selectivity for ERbeta vs ERalpha, was identified via high-throughput screening utilizing an ERbeta SPA-based binding assay. Subsequent analogue preparation resulted in the identification of compounds such as 21 and 43 that display 25- to 30-fold selectivity for ERbeta with potencies in the 10-30 nM range. These compounds profile as full antagonists at ERbeta and weak partial agonists at ERalpha in a cell-based reporter gene assay. In addition, the X-ray crystal structure of compound 15 complexed with the ligand binding domain of ERbeta has been solved and was utilized in the design of more conformationally restrained analogues such as 31 in an attempt to increase selectivity for the ERbeta subtype.
Cited by 161 works. doi:10.1021/jm020291h
Authors
- Brad R. Henke
- Thomas G. Consler
- Ning Fei Go
- Ron L. Hale
- Dana R. Hohman
- Stacey A. Jones
- Amy Tsai Lu
- Linda B. Moore
- John T. Moore
- Lisa A. Orband‐Miller
- R. Graham Robinett
- Jean Shearin
- Paul K. Spearing
- Eugene L. Stewart
- Philip Turnbull
- Susan L. Weaver
- Shawn P. Williams
- G. Bruce Wisely
- Millard H. Lambert
References
- Molecular basis of agonism and antagonism in the oestrogen receptor
- The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen
- ERβ: Identification and characterization of a novel human estrogen receptor
- Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
- Estrogen Therapy in Postmenopausal Women
- The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site
- Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes
- Structure at 1.65 Å of RhoA and its GTPase-activating protein in complex with a transition-state analogue
- Differential Response of Estrogen Receptor α and Estrogen Receptor β to Partial Estrogen Agonists/Antagonists
- Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women